48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE.

48-year-old woman who underwent CEM to evaluate two masses (arrows) in right breast. CEM obtained in following order: (A) craniocaudal (CC) view of right breast; (B) CC view of left breast; (C) mediolateral oblique (MLO) view of right breast; and (D) MLO view of left breast. Degree of background parenchymal enhancement (BPE) increases over time after contrast agent injection. (A) CC view of right breast shows mild BPE, whereas subsequently obtained (B) CC view of left breast shows moderate BPE. Based on criteria 1 reflecting only first obtained CC view, degree of BPE is classified as mild; based on criteria 2 reflecting both obtained CC views, degree of BPE is classified as moderate. Histopathologic assessment from subsequent biopsy demonstrated both masses to be invasive ductal carcinoma. 

 


January 27, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), both menstrual status and menstrual cycle time are associated with the degree of early background parenchymal enhancement (BPE) on contrast-enhanced mammography (CEM), which could influence CEM interpretations. 

“Clinical factors, including history of breast cancer or breast cancer treatment, breast density, menstrual status, and time of menstrual cycle, are associated with degree of early BPE on CEM,” wrote corresponding author Yajia Gu from the department of radiology at Fudan University Shanghai Cancer Center in China. “In premenopausal patients, degree of BPE is lowest on days 8–14 of the menstrual cycle.” 

This AJR accepted manuscript included 207 patients (median age, 46 years) who underwent CEM between April 2020 and September 2021. Two radiologists independently assessed BPE degree on CEM (minimal, mild, moderate, or marked) based on two criteria: using the first of four obtained views; using the first two of four obtained views. Reviewing electronic medical records for clinical factors, the radiologist pair reached consensus for breast density via CEM. 

Ultimately, degree of early BPE on CEM was negatively associated with age, history of breast cancer, chemotherapy or radiation therapy, as well as perimenopausal and postmenopausal status. Meanwhile, early BPE degree on this modality was positively associated with dense breasts and premenopausal status with irregular cycles.   

Acknowledging their retrospective study’s small sample size, given the potential impact of BPE on diagnostic performance, “the findings have implications for CEM scheduling and interpretation,” the authors of this AJR accepted manuscript added. 

For more information: www.arrs.org 

Related Breast Imaging Content: 

Single vs. Multiple Architectural Distortion on Digital Breast Tomosynthesis 

Today's Mammography Advancements  

Digital Breast Tomosynthesis Spot Compression Clarifies Ambiguous Findings  

AI DBT Impact on Mammography Post-breast Therapy  

ImageCare Centers Unveils PINK Better Mammo Service Featuring Profound AI  

Radiologist Fatigue, Experience Affect Breast Imaging Call Backs  

Fewer Breast Cancer Cases Between Screening Rounds with 3-D Mammography 

Study Finds Racial Disparities in Access to New Mammography Technology 

American College of Radiology (ACR) Launches Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) in Collaboration With GE Healthcare and the Breast Cancer Research Foundation 


Related Content

News | Ultrasound Women's Health

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results ...

Time September 30, 2026
arrow
News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Breast Imaging

Sept. 10, 2026 — An artificial intelligence model that analyzes women's past and recent annual 3D mammograms is more ...

Time September 10, 2026
arrow
News | Ultrasound Women's Health

Sept. 3, 2026 — Royal Philips has introduced the eV14-2v transvaginal transducer, expanding its obstetrics and ...

Time September 04, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
Subscribe Now